Yes, multiple myeloma is a blood cancer. Specifically, it is a cancer of plasma cells, a type of white blood cell that normally produces antibodies to fight infections. These cancerous plasma cells multiply uncontrollably in the bone marrow, which is the soft tissue inside bones where blood cells are made. Because it originates in blood-forming cells rather than in an organ like the lung or colon, multiple myeloma falls squarely in the category of hematologic (blood) cancers alongside leukemia and lymphoma.
What Makes It a Blood Cancer
Blood cancers are defined by where they start: in cells that are part of the blood or immune system. Multiple myeloma begins when a single plasma cell in the bone marrow acquires genetic changes that cause it to divide without stopping. These abnormal plasma cells crowd out healthy blood-producing cells and churn out a dysfunctional protein that serves no immune purpose.
As the malignant plasma cells accumulate, they displace the normal cell lines in the bone marrow. This leads to three common blood-related problems: low red blood cell counts (anemia), low white blood cell counts that increase infection risk, and low platelet counts that make bleeding and bruising more likely. These consequences are a hallmark of blood cancers in general, where the disease disrupts normal blood production from the inside out.
How It Differs From Leukemia and Lymphoma
All three are blood cancers, but they behave differently in the body. In leukemia, cancerous cells circulate freely through the blood and bone marrow. In lymphoma, abnormal immune cells tend to cluster into masses or tumors in the lymph nodes and lymphatic tissues. Myeloma sits in a distinct category: it is a tumor of the bone marrow itself, involving one specific subset of white blood cells (plasma cells) that produce a distinctive abnormal protein.
Because myeloma cells live primarily in the bone marrow rather than flowing through the bloodstream or forming lymph node tumors, the disease causes a unique pattern of damage. Myeloma cells directly stimulate the cells responsible for breaking down bone tissue while simultaneously suppressing the cells that rebuild it. This creates “holes” in the bones called lytic lesions, which can cause bone pain, fractures, and elevated calcium levels in the blood. That bone involvement is one of the clearest ways myeloma distinguishes itself from other blood cancers.
Common Symptoms
Myeloma often develops slowly, and some people have no symptoms at first. When symptoms do appear, they typically reflect the damage happening in the bone marrow and bones:
- Bone pain: especially in the spine, ribs, and hips, often the first noticeable symptom
- Fatigue and weakness: caused by anemia as healthy red blood cells get crowded out
- Frequent infections: because the immune system’s normal antibody production is suppressed
- Kidney problems: the abnormal protein produced by myeloma cells can damage the kidneys over time
- Unexplained fractures: bones weakened by lytic lesions may break with minimal trauma
Precursor Conditions
Multiple myeloma doesn’t typically appear out of nowhere. Nearly all cases are preceded by a condition called MGUS (monoclonal gammopathy of undetermined significance), in which abnormal plasma cells are present but haven’t yet caused harm. MGUS is surprisingly common, particularly in older adults, and the vast majority of people with it never develop cancer. On average, about 1% of people with MGUS progress to multiple myeloma each year.
Between MGUS and active myeloma, there is an intermediate stage called smoldering myeloma. At this point, the number of abnormal plasma cells is higher, but the disease still isn’t causing organ damage or bone lesions. Doctors monitor smoldering myeloma closely, as the risk of progression is higher than with MGUS alone. Treatment typically doesn’t begin until the disease becomes active and starts causing measurable harm.
How It Is Treated
Treatment for multiple myeloma has evolved dramatically. While a cure remains rare, most people now live significantly longer than they did even two decades ago. The five-year relative survival rate is currently about 64%, and that number continues to improve as newer therapies reach patients.
Modern treatment usually combines drugs from multiple classes. One major category works by blocking the cellular machinery that cancer cells rely on to dispose of waste proteins, essentially causing the malignant cells to choke on their own byproducts. Another class modifies the immune system’s behavior to help it recognize and attack myeloma cells. These two types of drugs form the backbone of most initial treatment plans and are often paired with steroids to enhance their effectiveness.
For patients whose disease returns after initial treatment, newer options have expanded considerably. Engineered antibodies can now latch onto specific markers on myeloma cells and recruit the body’s own immune cells to destroy them. Some of these antibodies are designed to grab onto both a myeloma cell and a T cell simultaneously, forcing them into close contact so the immune cell can do its job. Drugs that protect bones from further damage are also a routine part of care, since the skeletal complications of myeloma can significantly affect quality of life.
Many patients who are healthy enough undergo a stem cell transplant as part of their treatment. This involves using high-dose chemotherapy to wipe out the bone marrow and then replacing it with healthy stem cells, usually collected from the patient’s own blood beforehand. The transplant doesn’t cure myeloma in most cases, but it can deepen the response to treatment and extend the period before the disease returns.
Who Gets Multiple Myeloma
Multiple myeloma is primarily a disease of older adults. The median age at diagnosis is around 70, and it is uncommon before age 45. Men are diagnosed slightly more often than women, and Black Americans develop myeloma at roughly twice the rate of white Americans, for reasons that are not fully understood but likely involve both genetic susceptibility and differences in the prevalence of MGUS.
There are no widely established lifestyle factors that dramatically increase risk the way smoking increases lung cancer risk. Obesity, exposure to certain industrial chemicals, and a family history of myeloma or MGUS are associated with modestly higher risk, but most people diagnosed have no obvious risk factor beyond age.